Glenmede Trust CO Na Catalyst Pharmaceuticals, Inc. Transaction History
Glenmede Trust CO Na
- $18.2 Billion
- Q1 2025
A detailed history of Glenmede Trust CO Na transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Glenmede Trust CO Na holds 85,977 shares of CPRX stock, worth $2.09 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
85,977
Previous 94,686
9.2%
Holding current value
$2.09 Million
Previous $1.98 Million
5.47%
% of portfolio
0.01%
Previous 0.01%
Shares
14 transactions
Others Institutions Holding CPRX
# of Institutions
388Shares Held
99.3MCall Options Held
37KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$455 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.5MShares$207 Million0.0% of portfolio
-
State Street Corp Boston, MA5.53MShares$135 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.42MShares$83.2 Million2.1% of portfolio
-
Goldman Sachs Group Inc New York, NY3.14MShares$76.3 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.5B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...